CIPHER PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.5 CAD | 0.00% |
|
0.00% | +53.43% |
| Mar. 15 | Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024 | |
| Mar. 14 | Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 40.47 | 25.14 | 46.45 | 96.48 | 133.1 | 204.9 | - | - |
| Enterprise Value (EV) 1 | 40.47 | 25.14 | 46.45 | 96.48 | 133.1 | 204.9 | 204.9 | 204.9 |
| P/E ratio | 10.5 x | 4.68 x | 4.83 x | 2.71 x | 5.12 x | 17.3 x | 19.6 x | 19.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.26 x | 0.94 x | 1.67 x | 3.39 x | 4.65 x | 7.1 x | 6.99 x | 7.03 x |
| EV / Revenue | 1.26 x | 0.94 x | 1.67 x | 3.39 x | 4.65 x | 7.1 x | 6.99 x | 7.03 x |
| EV / EBITDA | 2.24 x | 1.48 x | 2.64 x | 5.64 x | 7.74 x | 11.9 x | 11.6 x | 11.5 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 1 x | 0.65 x | 0.93 x | 1.11 x | 1.29 x | 0.84 x | 0.83 x | 0.8 x |
| Nbr of stocks (in thousands) | 26,981 | 27,034 | 26,241 | 25,124 | 24,022 | 24,107 | - | - |
| Reference price 2 | 1.500 | 0.9300 | 1.770 | 3.840 | 5.540 | 8.500 | 8.500 | 8.500 |
| Announcement Date | 3/25/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 32.21 | 26.86 | 27.74 | 28.43 | 28.6 | 28.87 | 29.33 | 29.17 |
| EBITDA 1 | 18.03 | 17.01 | 17.59 | 17.11 | 17.19 | 17.19 | 17.7 | 17.82 |
| EBIT | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 8.175 | 8.126 | 13.98 | 15.79 | 17.14 | 13.81 | 14.26 | 13.91 |
| Net income 1 | 2.72 | 5.655 | 9.807 | 36.63 | 27.55 | 12.94 | 13.31 | 13.38 |
| Net margin | 8.44% | 21.05% | 35.36% | 128.83% | 96.32% | 44.83% | 45.36% | 45.88% |
| EPS 2 | 0.1432 | 0.1989 | 0.3666 | 1.417 | 1.081 | 0.4917 | 0.4330 | 0.4335 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/25/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.683 | 7.398 | 7.031 | 7.089 | 6.409 | 6.751 | 6.589 | 7.086 | 8.352 | 6.65 | 6.813 | 7.345 | 7.308 | 7.331 | 7.713 |
| EBITDA 1 | 2.786 | 5.148 | 4.026 | 4.555 | 3.52 | 4.328 | 4.276 | 4.123 | 4.964 | 3.871 | 4.53 | 4.125 | 4.463 | 4.058 | 4.33 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | 1.65 | 4.949 | - | - | 3.069 | 4.035 | 3.652 | 4.248 | 4.297 | 4.976 | - | - | - | - | - |
| Net income | 1.002 | 3.552 | - | - | 3.549 | 27.07 | 3.541 | 4.115 | 9.677 | 10.35 | - | - | - | - | - |
| Net margin | 17.63% | 48.02% | - | - | 55.38% | 400.92% | 53.75% | 58.07% | 115.87% | 155.59% | - | - | - | - | - |
| EPS 2 | 0.0378 | 0.1390 | - | - | 0.1337 | 1.059 | 0.1349 | 0.1608 | 0.3716 | 0.4055 | 0.1350 | 0.1490 | 0.1760 | 0.1490 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/17/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/16/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/14/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 9.42% | 15% | 21.7% | 41.6% | 25.3% | 12.5% | 1.4% | 3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.490 | 1.440 | 1.900 | 3.470 | 4.280 | 10.20 | 10.30 | 10.60 |
| Cash Flow per Share 2 | -0.2100 | 0.5300 | 0.6500 | 0.5600 | 0.8500 | 0.3000 | 0.3000 | 0.2400 |
| Capex 1 | 1.14 | 0.01 | - | 0.11 | 0.03 | - | - | - |
| Capex / Sales | 3.54% | 0.05% | - | 0.39% | 0.1% | - | - | - |
| Announcement Date | 3/25/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.5
CAD
Average target price
7.617
CAD
Spread / Average Target
-10.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +53.43% | 150M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CPH Stock
- Financials Cipher Pharmaceuticals Inc.
